Literature DB >> 19601801

Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) in atherogenesis: a brief review.

Allison B Reiss1, Kamran Anwar, Peter Wirkowski.   

Abstract

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a scavenger receptor that primarily binds and regulates oxidized low-density lipoprotein (LDL). Expression of LOX-1 is regulated by a feed-forward system stimulated by oxidized LDL (oxLDL), a major component of atherosclerosis. LOX-1 is a homodimer with a reactive backbone that can bind to a host of different ligands, including small molecules, and whole cells. LOX-1 is involved in many intercellular, intracellular, and molecular processes that are atherogenic. LOX-1 levels are elevated within atherosclerotic plaques and its expression is induced by proinflammatory cytokines. The ability of LOX-1 to bind many different ligands and control several atherogenic processes makes this receptor a likely vascular disease biomarker as well as an ideal choice for drug therapy aimed at preventing cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19601801     DOI: 10.2174/092986709788681994

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  12 in total

1.  The oxidized low-density lipoprotein receptor mediates vascular effects of inhaled vehicle emissions.

Authors:  Amie K Lund; JoAnn Lucero; Melissa Harman; Michael C Madden; Jacob D McDonald; Jean Clare Seagrave; Matthew J Campen
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

Review 2.  Regulation of foam cells by adenosine.

Authors:  Allison B Reiss; Bruce N Cronstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

3.  OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling.

Authors:  Sungwoo Ryoo; Anil Bhunia; Fumin Chang; Artin Shoukas; Dan E Berkowitz; Lewis H Romer
Journal:  Atherosclerosis       Date:  2010-11-04       Impact factor: 5.162

4.  Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.

Authors:  Yong Yang; Yan-Fu Wang; Xiao-Fang Yang; Zhao-Hui Wang; Yi-Tian Lian; Ying Yang; Xiao-Wei Li; Xiang Gao; Jian Chen; Yan-Wen Shu; Long-Xian Cheng; Yu-Hua Liao; Kun Liu
Journal:  J Lipid Res       Date:  2012-10-24       Impact factor: 5.922

Review 5.  Molecular imaging to identify the vulnerable plaque--from basic research to clinical practice.

Authors:  Dennis H M Kusters; Jan Tegtmeier; Leon J Schurgers; Chris P M Reutelingsperger
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

6.  Chronic Aerobic Exercise Decreases Lectin-Like Low Density Lipoprotein (LOX-1) Receptor Expression in Heart of Diabetic Rat.

Authors:  Simin Riahi; Mohammad Taghi Mohammadi; Vahid Sobhani; Shima Ababzadeh
Journal:  Iran Biomed J       Date:  2015-10-13

7.  Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention.

Authors:  Junfeng Liu; Yunde Liu; Kegang Jia; Zhixiao Huo; Qianyu Huo; Zhili Liu; Yongshu Li; Xuejing Han; Rong Wang
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

8.  Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism.

Authors:  Q Dong; R Xiang; D Y Zhang; S Qin
Journal:  Braz J Med Biol Res       Date:  2013-09-19       Impact factor: 2.590

Review 9.  Microglia Ontology and Signaling.

Authors:  Ayman ElAli; Serge Rivest
Journal:  Front Cell Dev Biol       Date:  2016-06-29

10.  LOX-1: A potential driver of cardiovascular risk in SLE patients.

Authors:  Divya Sagar; Ranjitha Gaddipati; Emily L Ongstad; Nicholas Bhagroo; Ling-Ling An; Jingya Wang; Mehdi Belkhodja; Saifur Rahman; Zerai Manna; Michael A Davis; Sarfaraz Hasni; Richard Siegel; Miguel Sanjuan; Joseph Grimsby; Roland Kolbeck; Sotirios Karathanasis; Gary P Sims; Ruchi Gupta
Journal:  PLoS One       Date:  2020-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.